Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Pharmascience Group Share News (OXP)

  • There is currently no data for OXP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Pharmascience To Test Improvements To Technology Platform

Wed, 09th Nov 2016 10:29

LONDON (Alliance News) - AIM-listed Oxford Pharmascience Group PLC said Wednesday that it is strengthening its intellectual property rights over its technology platform, ahead of clinical studies on improvements to its drug assets.

Oxford Pharmascience said it is continuing commercialisation discussions over its lead assets, OXPzero Ibuprofen and OXPzero Naprozen, and it has filed for a new UK patent over technical modifications to its OXPzero technology platform.

The company said it will now progress to conduct UK-based Phase 1 exploratory pharmacokinetic clinical studies to validate the performance of its technology improvements, beginning with OXPzero Ibuprofen. Dosing is expected to start early in 2017.

Oxford Pharmascience said it remains well-funded, with GBP22.6 million in cash balances at October 31.

"In parallel to the ongoing commercial partnering activities, we are pleased to see OXPzero Ibuprofen going back into the clinic and our OXPzero NSAIDs IP protection being strengthened. We look forward to receiving advice from the FDA on our over-the-counter and prescription OXPzeroTM Ibuprofen product development strategies," said Marcelo Bravo, chief executive officer.

Shares in Oxford Pharmascience were up 1.0% at 2.02 pence Wednesday.

By Adam Clark; adamclark@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
29 Sep 2014 12:08

Oxford Pharmascience Posts Widened Loss As It Ups Investment

Read more
15 Sep 2014 10:12

Oxford Pharmascience Progressing Low Gastric-Irritation Naproxen

Read more
17 Jun 2014 11:04

Oxford Pharmascience Agrees Inellare Extension With Brazil's Aché

LONDON (Alliance News) - Oxford Pharmascience Group PLC Tuesday said it has agreed a line extension with Brazilian pharmaceuticals partner Aché Pharmaceuticos, for a new version of the calcium and vitamin D chew tablet Inellare. The specialty pharmaceutical company said sales of the new ver

Read more
2 Jun 2014 10:06

Oxford Pharmascience Sees Positive OXP001 Study Results

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday that it had seen positive results from a pilot clinical study of its reduced gastric irritation ibuprofen product OXP001. The proof of concept clinical study was to determine the extent of upper gastrointestinal irritation

Read more
30 Apr 2014 10:34

Oxford Pharmascience Appoints Research Firm For Safestat Pilot Study

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Wednesday it has appointed Quotient Clinical to undertake its early clinical development programme for its OXP003 Safestat product proof of concept study. The specialty pharmaceutical firm said it has appointed the company to unde

Read more
26 Mar 2014 15:54

Carnival Chairman reduces stake by around a quarter

Micky Arison, the long-standing Chairman of cruise line operator Carnival Corp., docked a batch of shares earlier this week ahead of its better-than-expected first quarter trading update. Arison offloaded 525,348 at $40.09 each, reducing his stake to 104.52m shares. The group on Tuesday reported

Read more
26 Mar 2014 10:53

DIRECTOR DEALINGS: Oxford Pharmascience Chair Buys 1 Million Shares

LONDON (Alliance News) - Oxford Pharmascience Group PLC Wednesday said Non-Executive Chairman David Norwood bought 1 million shares at a price of 4.3 pence per share Tuesday. Following this transaction, Norwood now holds 106 million shares, which represents 10.62% stake in the firm. S

Read more
17 Mar 2014 10:54

Oxford Pharmascience Group Appoints R&D Head

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday it has appointed a Director of research and development to manage the firms' development activities. Dr Liz King has joined to lead and execute the company's development programme focused on the company's two main medicines

Read more
10 Mar 2014 10:19

Oxford Pharmascience Starts Dosing Subjects In Ibuprofen Study

LONDON (Alliance News) - Oxford Pharmascience Group PLC Monday said it has begun dosing subjects in the pilot clinical study of its OXP001 400 milligram Ibuprofen treatment. The company redevelops existing medicines to try and make them better, safer and easier to take and is trying to dev

Read more
5 Mar 2014 10:39

Oxford Pharmascience Pretax Loss Widens, New CEO Appointed

LONDON (Alliance News) - Oxford Pharmascience Group PLC Wednesday said it appointed a new chief executive and saw a widened pretax loss in 2013 due to increased research and development costs, as it advanced its product programmes towards commercialisation. The pharmaceutical technology com

Read more
7 Feb 2014 08:19

Oxford Pharmascience Gets Approval For Ibuprofen Product Trial

LONDON (Alliance News) - Oxford Pharmascience Group PLC Friday said its clinical trial application for OXP001 400 milogram reduced gastric irritation Ibuprofen has received approval from the UK Medicines and Healthcare Products Regulatory Agency and the Ethics Review Committee. The company,

Read more
26 Nov 2013 12:52

Oxford Pharmascience Brazilian Partner Launches Sugar-Free Vitamin Chew

Read more
26 Nov 2013 08:25

AIM IN BRIEF: Chamberlin Swings To Half-Year Loss, Suspends Dividend

Read more
31 Oct 2013 13:55

Oxford Pharmascience Raises GBP4M Through 100M Share Placing

Read more
21 Oct 2013 08:02

Oxford Pharmascience Completes Ibuprofen Formulation

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.